235 citations
,
September 2004 in “The Journal of urology/The journal of urology” This review discusses the role of dihydrotestosterone in benign prostatic hyperplasia and reports no new results; the authors highlight 5alpha-reductase inhibitors as a well-established treatment option.
224 citations
,
February 2013 in “The Journal of clinical investigation/The journal of clinical investigation” This study identifies SOX9 as a critical downstream effector of ERG in TMPRSS2:ERG fusion-positive prostate cancer, indicating its role in tumor invasion and growth.
193 citations
,
August 1985 in “Endocrinology” This study found significant species differences in the enzyme activity and inhibitor affinities of prostatic 5α-reductases from rats, dogs, and humans, with variable potencies for different 3-oxo-4-azasteroid inhibitors across species.
154 citations
,
March 2012 in “Indian Journal of Surgical Oncology” This review re-evaluates the role of Serum Prostate Specific Antigen in prostate cancer diagnosis, suggesting it is most reliable for detecting cancer recurrences after treatment.
153 citations
,
April 2009 in “Urology” This article reviews potential prevention and intervention strategies for prostate cancer, including 5alpha-reductase inhibition, but reports no new clinical findings.